{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:24:14Z","timestamp":1791289454571,"version":"4.3.0"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T00:00:00Z","timestamp":1530489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,25]]},"DOI":"10.1093\/schbul\/sby095","type":"journal-article","created":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T11:07:47Z","timestamp":1528888067000},"page":"639-646","source":"Crossref","is-referenced-by-count":135,"title":["How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials"],"prefix":"10.1093","volume":"45","author":[{"given":"Myrto T","family":"Samara","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Klinikum rechts der Isar, Ismaningerstr, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriani","family":"Nikolakopoulou","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Salanti","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Klinikum rechts der Isar, Ismaningerstr, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,2]]},"reference":[{"key":"2019042516034156800_CIT0001","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatry"},{"key":"2019042516034156800_CIT0002","first-page":"62","article-title":"Clozapine in treatment-resistant schizophrenics","volume":"24","author":"Kane","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"2019042516034156800_CIT0003","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/schbul\/16.4.551","article-title":"Defining treatment refractoriness in schizophrenia","volume":"16","author":"Brenner","year":"1990","journal-title":"Schizophr Bull"},{"key":"2019042516034156800_CIT0004","first-page":"431","article-title":"Conventional versus novel antipsychotics: changing concepts and clinical implications","volume":"24","author":"Remington","year":"1999","journal-title":"J Psychiatry Neurosci"},{"key":"2019042516034156800_CIT0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000319806","article-title":"Assessment of therapy-resistant schizophrenia","volume-title":"Therapy-Resistant Schizophrenia","author":"Lindenmayer","year":"2010"},{"issue":"2","key":"2019042516034156800_CIT0006","first-page":"261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull","volume":"13","author":"Kay","year":"1987"},{"key":"2019042516034156800_CIT0007","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"2019042516034156800_CIT0008","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"2019042516034156800_CIT0009","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.13049su1c.02","article-title":"Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application","volume":"75","author":"Leucht","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"2019042516034156800_CIT0010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0924-977X(96)00392-6","article-title":"Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial","volume":"7","author":"Beasley","year":"1997","journal-title":"Eur Neuropsychopharmacol"},{"key":"2019042516034156800_CIT0011","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02245617","article-title":"Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial","volume":"124","author":"Beasley","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"2019042516034156800_CIT0012","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s002130050361","article-title":"Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group","volume":"132","author":"M\u00f6ller","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"2019042516034156800_CIT0013","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am J Psychiatry"},{"key":"2019042516034156800_CIT0014","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders","volume":"17","author":"Tran","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"2019042516034156800_CIT0015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s002130050614","article-title":"Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology\u2014a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-\/D2-like antagonist. The Amisulpride Study Group","volume":"137","author":"Wetzel","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"2019042516034156800_CIT0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1998.tb10044.x","article-title":"Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group","volume":"98","author":"Puech","year":"1998","journal-title":"Acta Psychiatr Scand"},{"key":"2019042516034156800_CIT0017","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-1781(99)00075-X","article-title":"Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride Study Group","volume":"88","author":"Peuskens","year":"1999","journal-title":"Psychiatry Res"},{"key":"2019042516034156800_CIT0018","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0924-9338(00)00401-6","article-title":"Amisulpride has a superior benefit\/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group)","volume":"15","author":"Carri\u00e8re","year":"2000","journal-title":"Eur Psychiatry"},{"key":"2019042516034156800_CIT0019","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00004850-200015010-00002","article-title":"Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group","volume":"15","author":"Colonna","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"key":"2019042516034156800_CIT0020","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0893-133X(02)00375-5","article-title":"Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study","volume":"27","author":"Sechter","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"2019042516034156800_CIT0021","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1176\/appi.ajp.160.8.1396","article-title":"Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol","volume":"160","author":"Lieberman","year":"2003","journal-title":"Am J Psychiatry"},{"key":"2019042516034156800_CIT0022","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"2019042516034156800_CIT0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2005.07.038","article-title":"One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia","volume":"81","author":"Keefe","year":"2006","journal-title":"Schizophr Res"},{"key":"2019042516034156800_CIT0024","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","article-title":"Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia","volume":"162","author":"Breier","year":"2005","journal-title":"Am J Psychiatry"},{"key":"2019042516034156800_CIT0025","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/01.jcp.0000236658.16286.25","article-title":"Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning","volume":"26","author":"Kinon","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"2019042516034156800_CIT0026","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/schbul\/19.2.287","article-title":"Psychopharmacologic treatment of schizophrenia","volume":"19","author":"Kane","year":"1993","journal-title":"Schizophr Bull"},{"key":"2019042516034156800_CIT0027","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am J Psychiatry"},{"key":"2019042516034156800_CIT0028","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/sj.npp.1301325","article-title":"Defining \u2018response\u2019 in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs","volume":"32","author":"Leucht","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"438","key":"2019042516034156800_CIT0029","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.2008.01308.x","article-title":"Definitions of response and remission in schizophrenia: recommendations for their use and their presentation","author":"Leucht","year":"2009","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"2019042516034156800_CIT0030","volume-title":"ECDEU Assessment Manual for Psychopharmacology \u2014Revised","author":"Guy","year":"1976"},{"key":"2019042516034156800_CIT0031","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"Br J Psychiatry"},{"key":"2019042516034156800_CIT0032","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr Res"},{"key":"2019042516034156800_CIT0033","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"2019042516034156800_CIT0034","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.4088\/JCP.v67n1120","article-title":"Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia","volume":"67","author":"Leucht","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"2019042516034156800_CIT0035","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.schres.2007.09.006","article-title":"Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI","volume":"98","author":"Levine","year":"2008","journal-title":"Schizophr Res"},{"key":"2019042516034156800_CIT0036","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients","volume":"13","author":"Chouinard","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"2019042516034156800_CIT0037","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"2019042516034156800_CIT0038","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am J Psychiatry"},{"key":"2019042516034156800_CIT0039","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1192\/bjp.166.6.712","article-title":"Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group","volume":"166","author":"Peuskens","year":"1995","journal-title":"Br J Psychiatry"},{"key":"2019042516034156800_CIT0040","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0447.1992.tb01473.x","article-title":"Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study","volume":"85","author":"Claus","year":"1992","journal-title":"Acta Psychiatr Scand"},{"key":"2019042516034156800_CIT0041","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1600-0447.1993.tb03480.x","article-title":"Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations","volume":"88","author":"H\u00f8yberg","year":"1993","journal-title":"Acta Psychiatr Scand"},{"key":"2019042516034156800_CIT0042","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/oxfordjournals.schbul.a006925","article-title":"Clinical profile of an atypical antipsychotic: risperidone","volume":"28","author":"Davis","year":"2002","journal-title":"Schizophr Bull"},{"key":"2019042516034156800_CIT0043","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1600-0447.2005.00659.x","article-title":"Standardized remission criteria in schizophrenia","volume":"113","author":"van Os","year":"2006","journal-title":"Acta Psychiatr Scand"},{"key":"2019042516034156800_CIT0044","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/schbul\/sbp124","article-title":"Should the PANSS be rescaled","volume":"36","author":"Obermeier","year":"2010","journal-title":"Schizophr Bull"},{"key":"2019042516034156800_CIT0045","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/schbul\/sbq016","article-title":"The PANSS should be rescaled","volume":"36","author":"Leucht","year":"2010","journal-title":"Schizophr Bull"},{"key":"2019042516034156800_CIT0046","volume-title":"The Cochrane Library","author":"Adams","year":"2006"},{"key":"2019042516034156800_CIT0047","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.euroneuro.2012.11.004","article-title":"Equipercentile linking of the BPRS and the PANSS","volume":"23","author":"Leucht","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"2019042516034156800_CIT0048","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0447.1990.tb05305.x","article-title":"A double-blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia","volume":"358","author":"McCreadie","year":"1990","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"2019042516034156800_CIT0049","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0920-9964(94)00088-P","article-title":"Variability in BPRS definitions of positive and negative symptoms","volume":"17","author":"Nicholson","year":"1995","journal-title":"Schizophr Res"},{"key":"2019042516034156800_CIT0050","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00005053-198702000-00006","article-title":"Depression, Parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics","volume":"175","author":"Prosser","year":"1987","journal-title":"J Nerv Ment Dis"},{"key":"2019042516034156800_CIT0051","year":"2011"},{"key":"2019042516034156800_CIT0052","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am J Psychiatry"},{"key":"2019042516034156800_CIT0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007999709113338","article-title":"Treatment-resistant schizophrenia\u2014the role of clozapine","volume":"14","author":"Meltzer","year":"1997","journal-title":"Curr Med Res Opin"},{"key":"2019042516034156800_CIT0054","volume-title":"Pharmacologic Treatment of Schizophrenia","author":"Conley","year":"2007","edition":"3"},{"key":"2019042516034156800_CIT0055","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1176\/ajp.154.4.475","article-title":"Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance","volume":"154","author":"Meltzer","year":"1997","journal-title":"Am J Psychiatry"},{"key":"2019042516034156800_CIT0056","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s001270050184","article-title":"Age at onset of schizophrenia and neuroleptic dosage","volume":"34","author":"Dernovsek","year":"1999","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"2019042516034156800_CIT0057","doi-asserted-by":"crossref","first-page":"505","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon","article-title":"Clinical predictors of therapeutic response to antipsychotics in schizophrenia","volume":"16","author":"Carbon","year":"2014","journal-title":"Dialogues Clin Neurosci"},{"key":"2019042516034156800_CIT0058","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.4088\/JCP.13m08853","article-title":"Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials","volume":"75","author":"Rabinowitz","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"2019042516034156800_CIT0059","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1176\/appi.ajp.2017.16091016","article-title":"The long-term effects of antipsychotic medication on clinical course in schizophrenia","volume":"174","author":"Goff","year":"2017","journal-title":"Am J Psychiatry"},{"key":"2019042516034156800_CIT0060","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0193-953X(18)30176-X","article-title":"Predictors of response to neuroleptic treatment in schizophrenia","volume":"16","author":"Stern","year":"1993","journal-title":"Psychiatr Clin North Am"},{"key":"2019042516034156800_CIT0061","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1001\/jamapsychiatry.2014.2127","article-title":"Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies","volume":"72","author":"Furukawa","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"2019042516034156800_CIT0062","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"2019042516034156800_CIT0063","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am J Psychiatry"},{"key":"2019042516034156800_CIT0064","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","article-title":"Placebo response in antipsychotic clinical trials: a meta-analysis","volume":"71","author":"Rutherford","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"2019042516034156800_CIT0065","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","article-title":"Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected","volume":"60","author":"Agid","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"2019042516034156800_CIT0066","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.biopsych.2005.02.023","article-title":"Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended","volume":"57","author":"Leucht","year":"2005","journal-title":"Biol Psychiatry"},{"key":"2019042516034156800_CIT0067","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","article-title":"Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review","volume":"172","author":"Samara","year":"2015","journal-title":"Am J Psychiatry"},{"key":"2019042516034156800_CIT0068","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0920-9964(02)00322-5","article-title":"Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice","volume":"61","author":"Rabinowitz","year":"2003","journal-title":"Schizophr Res"},{"key":"2019042516034156800_CIT0069","first-page":"369","article-title":"National Institute of Mental Health Psychopharmacology Research Branch Collaborative Study Group. Differences in clinical effects of three phenothiazines in \u201cacute\u201d schizophrenia","volume":"28","year":"1967","journal-title":"Dis Nerv Syst"},{"key":"2019042516034156800_CIT0070","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.npp.1300157","article-title":"Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine","volume":"28","author":"Lieberman","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"2019042516034156800_CIT0071","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1176\/ajp.156.4.544","article-title":"Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder","volume":"156","author":"Robinson","year":"1999","journal-title":"Am J Psychiatry"},{"key":"2019042516034156800_CIT0072","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.biopsych.2010.01.012","article-title":"Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories","volume":"68","author":"Levine","year":"2010","journal-title":"Biol Psychiatry"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/45\/3\/639\/28530145\/sby095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T16:36:19Z","timestamp":1661445379000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/45\/3\/639\/5047593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,2]]},"references-count":72,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,7,2]]},"published-print":{"date-parts":[[2019,4,25]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sby095","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2018,7,2]]}}}